We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
Date | Subject | Author | Discuss |
---|---|---|---|
31/5/2017 10:57 | Big breakout if we can get over 1707p happy holding long term and adding on the dips as well as trading the dips & pops. Decent divi too for a long term hold. | ny boy | |
31/5/2017 10:55 | ianood - you will see from my thread my moves against sterling. Gains are huge and positions remain open. GSK is a neat vehicle that does not mean someone has to go into the forex markets. | alphorn | |
31/5/2017 10:48 | Well just short Sterling then, however,it may need some b*lls at this level! | ianood | |
31/5/2017 10:03 | Could go a bit higher with GBP falling by the day. Real gains for domestic holders but not for foreign based funds/PIs. | alphorn | |
31/5/2017 07:43 | GC reiterates Hold,and £20 it is then ! | garycook | |
31/5/2017 07:32 | TM reiterates 'hold' and 2050p target | tradermichael | |
31/5/2017 07:20 | HSBC reiterates 'buy' and 1970p target | philanderer | |
30/5/2017 23:08 | Good FT article on the Gilead Sciences final trial results here: hxxps://www.ft.com/c Basically says this is good for GSK as they can maintain market share for ViiV (£4bn sales per year) | smokybenchod | |
30/5/2017 21:25 | @Phil, Just read that on SeekingAlpha Glaxo bucks the market on reduced threat to TIVICAY from Gilead's BIC/FTC/TAF, shares up 2%" On modestly higher volume as investors ratchet up the buying on the heels of Gilead Sciences' annou | fangorn2 | |
30/5/2017 21:21 | Drugmaker GlaxoSmithKline eked out gains of 29.5p to £16.73, after its rival Gilead’s new HIV drug bictegravir succeeded in four-late stage studies, but didn’t show any superiority to Glaxo’s established drug. Telegraph market report. | philanderer | |
30/5/2017 16:21 | Yep, here we go again, fab stock! | ny boy | |
30/5/2017 10:17 | Yep, keep buying those dips! | ny boy | |
26/5/2017 18:45 | Buy those dips Sir, great stock for dip buying and a great divi (quarterly too) 1715p target, still in play but need to close over 1652p first. | ny boy | |
26/5/2017 15:02 | i think the GDP reading over the pond is behind the USD strength. | sporazene2 | |
26/5/2017 14:48 | Two-edged sword: Corbyn more popular and pound weakens ..... GSK rises? | tradermichael | |
26/5/2017 09:57 | Berenberg upgrading this morning from 'hold' to 'buy' .. target 1885p | philanderer | |
26/5/2017 09:49 | Performing its forex hedge duties today. | alphorn | |
23/5/2017 16:17 | NY Boy Lol | montyhedge | |
23/5/2017 16:16 | Oh dear 1629 | mj19 | |
19/5/2017 16:24 | Going back up again to try and close above 1652p resistance | ny boy | |
19/5/2017 10:49 | Monty, you giving me a thumbs down on every one of my posts, knew it was you, advfn told me you have issues. | ny boy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions